Today, Arrayit Corporation (ARYC) CEO, Rene Schana, released a letter to shareholders detailing the company’s recent successes and future endeavors. The company, headquartered in Sunnyvale, CA, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities by focusing on proprietary life science technologies and consumables for disease prevention, treatment and cure. Schana’s letter provides useful information regarding their current status in the world market today.

ARYC began trading on the bulletin board in March, 2009 with a deliberate and measured strategy to introduce the company’s scientific accomplishments to its shareholders. Interest in the stock steadily increased as the company utilized its awareness campaign to announce future initiatives. After pioneering the development of research tools for genomics (the study of the genetic structure) and proteomics (the study of the proteins produced by the activity of specific genes), Arrayit is now entering the exciting field of diagnostics of disease states.

The company currently has microarray based diagnostic kits in late stages of development. The kits, designed for specific cancers and degenerative diseases, employ novel strategies that greatly improve the accuracy of the tests. Arrayit has demonstrated a unique ability to obtain consistent results, far surpassing its competitors. In preparation for product launch, Arrayit Diagnostics, Inc. recently opened sales offices in Houston, TX. Another company product, gene specific personalized treatments, are currently in their infancy. Additionally, the company’s recently announced initiatives with the CDC, Sandia National Laboratory and the Parkinson’s Institute are proceeding with remarkable results. Arrayit looks forward to becoming a major contributor in revolutionizing healthcare.

Schana’s letter also stated that Arrayit’s products are currently represented by 44 international distributors with a presence in over 50 nations. Sales have also increased by 41% for the third quarter of this year compared to last year’s numbers.

Arrayit is proud of its 13 years of experience with proven science and global success. The company acknowledges and thanks its shareholders for their support, with the hope that their products will provide much needed cost savings to the health care industry through early diagnosis and treatment.